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Research Question? Call the Office of Research at our central number: 413-794-3391
Research Pilot Award Program (RPAP) sees success over several years since its inception
The Research Pilot 
Award Program (RPAP) is 
an internal grants program 
designed to help UMMS-
Baystate faculty test 
study designs and collect 
preliminary data to support 
a larger external grant 
application. The program 
is underwritten com-
pletely with indirect funds 
obtained through existing 
federal grant awards
Beginning in the summer 
of 2016, the program has 
solicited applications and 
funded proposals each 
year. The application 
process is competitive, 
and funding depends on 
the number and quality of 
the applications, as well 
as the availability of funds.  
A committee of experi-
enced clinical research-
ers reviews and scores 
each application on three 
criteria: the experience 
of the investigator with 
conducting research, the 
feasibility and fundability 
of the proposed study, 
and whether the study is 
consistent with the mission 
of Baystate.
To date, the program has 
funded 16 clinical investiga-
tors across several depart-
ments and disciplines. The 
studies that have been 
completed have supported 
four grant applications, 
two published papers, and 
three further manuscripts 
in preparation. Moreover, 
these pilot studies have 
provided the investigators 
critical information about 
their protocols – patient 
eligibility, recruitment, sub-
ject compliance, measure-
ment of variables, required 
staffing, collaborations 
with external agencies, as 
examples. As these studies 
illustrate, it is difficult to 
overstate the importance 
of pilot studies: they tell 
us what works – and 
what doesn’t – enabling 
us to correct and modify 
our approaches, thereby 
producing more competi-
tive, feasible, and clinically-
relevant applications.
In this issue, we consider 
six RPAP studies that have 
been completed thus far.  
Future issues of The Inno-
vator will highlight ongoing 
and new RPAP studies and 
their principal investigators.
Paul Visintainer, PhD, oversees 
the RPAP program.
A Pilot Randomized Controlled Study of Non-Invasive Ventilatory Support for Acute Hypoxemic 
Respiratory Failure: High Flow Nasal Oxygen vs. Helmet-Non-Invasive vs. Mask-Non-Invasive 
Ventilation
Mark Tidswell, MD, Associate Professor of Medicine at UMass Medical School-Baystate; Associate Professor of Medicine, 
Tufts University School of Medicine
Non-invasive ventilatory 
modes such as nonin-
vasive positive pressure 
ventilation (NIPPV) and 
high-flow nasal cannula 
oxygen (HFNO) improve 
gas exchange, reverse 
hypoxemia, and may 
prevent intubation and 
the risks associated with 
invasive mechanical 
ventilation including need 
for sedation, delirium, lung 
injury, and nosocomial 
pneumonia.
Traditionally, NIPPV 
is delivered through a 
face-mask, but patient 
intolerance and air leaks 
are frequent with mask-
NIPPV. More recently, 
delivery of NIPPV through 
a helmet interface resulted 
in better tolerance than 
the face-mask and allowed 
the use of higher levels of 
positive pressure ventila-
tion (PEEP). 
No studies have yet 
compared all three modali-
ties (HFNO, mask-NIPPV 
and helmet-NIPPV) in a 
population of patients with 
hypoxemic respiratory 
failure. We proposed a 
pilot randomized con-
trolled trial to assess the 
effect of HFNO and hel-
met-NIPPV on intubation 
rate among patients with 
AHRF. These rates were 
compared with historical 
data obtained from the 
literature for mask-NIPPV 
intubation rates in similar 
population. Our main 
objective was to collect 
feasibility data on helmet 
NIPPV and other clinical 
elements in preparation 
for a full-scale randomized 
trial based on findings of 
this pilot study.
The project was 
terminated early because 
of difficulty achieving 
recruitment targets. What 
we learned is that the 
selection criteria were 
likely too rigid, which 
restricted the size of the 
potential patient pool and 
increased the time and 
effort required for patient 
screening. Finally, patient 
participation was lower 
than expected.  Mark Tidswell, MD
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Ksenia N. Tonyushkina, MD, Pediatric Endocrinologist 
and Assistant Professor of Pediatrics, UMass Medical 
School-Baystate
Engaging School Nurses in Diabetes 
Care Team to Improve Diabetes Self-
Management Skills, Adherence, and 
Glycemic Control in Children with T1DM
Ksenia N. Tonyushkina, MD
The overall objective 
of this pilot proposal was 
to evaluate the feasibility 
of monthly insulin dose 
adjustments for students with 
T1DM through collaboration 
between pediatric diabetes 
clinic and school nurses and 
impact of this intervention 
on diabetes control. Spe-
cifically, the goals were to 
evaluate the changes in A1C, 
diabetes self-management 
(DSM) behaviors in children 
with T1DM and their families, 
and to determine patient 
acceptance and satisfaction 
with this intervention.
We showed that school 
nurses could be engaged 
in a diabetes care team 
and model diabetes care at 
school with on-going sup-
port and education by the 
diabetes clinic team. We also 
found a trend toward better 
diabetes control during the 
school year vs. summer. The 
study suggested that involve-
ment of school nurses could 
improve care of high-risk 
students in need of intensive 
diabetes care coordination 
and supervision. 
My RPAP project led 
to two publications so 
far: “Cardiovascular and 
Somatic comorbidities 
and sleep measures 
using three hypopnea 
criteria in mild sleep 
disordered breathing: 
sex, age and body mass 
index differences in 
a retrospective sleep 
cohort” in Journal of 
Clinical Sleep Medicine2 
and “Flow Limitation/
Obstruction With Recov-
ery Breath (FLOW) Event 
For Improved Scoring of 




Overall, the RPAP 
provided me with the 
connections within the 
outstanding research, 
IRB, and epidemiology 
teams at Baystate and 
provided a foundation 
that has facilitated other 
research projects. I was 
able to be a research 
mentor for several 
summer students, 
college students, 
and PURCH medical 
students. This included 
becoming site PI for an 
investigational drug for 
Idiopathic Hypersomnia 
patients and research 
on readmission rates in 
inpatients undergoing 
sleep studies as well as 
the impact of COVID-19 
on sleep laboratories. 
Karin Johnson, MD, Vice Chair for Academic Affairs and 
Associate Professor, Department of Neurology, UMass Medical 
School-Baystate
Novel Scoring to Increase Sensitivity of 
Polysomnography (PSG) for Clinical Significant 
Obstructive Sleep Disordered Breathing
Karin Johnson, MD
Exercise Prescription in Cardiac 
Rehabilitation: A Pilot Randomized 
Controlled Trial
Quinn R. Pack, MD, MSc, Associate Professor of 
Medicine, UMass Medical School-Baystate; Adjunct 
Associate Professor of Medicine, Tufts University 
School of Medicine
As of October 2020, our 
RPAP was in the final stages 
of completion. We had 48 
total patients enroll and com-
plete baseline stress tests, 
of which 4 dropped out, 20 
discontinued the protocol 
prematurely due to COVID, 
and 24 completed the full 
protocol. We were successful 
in implementing our proto-
cols. Patients randomized 
to a target heart rate range 
increased their exercise 
intensity by about 5 beats 
per minute and increased 
their exercise capacity by 
an additional 1 MET. Patient 
satisfaction was high. 
In June 2020, Dr. Pack 
utilized these pilot findings to 
apply for a Physician-Scien-
tist Early Stage Investigator 
R01 grant from the NHBLI. In 
August 2020, Meredith Shea 
defended her dissertation 
and was awarded a PhD from 
Springfield College. In Octo-
ber 2020, she presented this 
data at the national meeting 
of the American Associa-
tion of Cardiovascular and 
Pulmonary Rehabilitation and 
won the Beginning Investiga-
tor Award. Three manuscripts 
are planned and are in vari-
ous stages of submission.  
Quinn R. Pack, MD, MSc
Improving Patient-Centered Outcomes for 
Adolescents with Depressive Illness through the 
Massachusetts Child Psychiatry Access Project 
(MCPAP)
Bruce Waslick, MD, Associate Professor of Psychiatry, UMass 
Medical School-Baystate
 There is increasing 
evidence that various 
models of primary care 
supports and enhance-
ments are effective in 
increasing detection 
of depressive illness in 
adolescents and facilitat-
ing families’ access to 
effective care services.
The Massachusetts 
Child Psychiatry Access 
Project (MCPAP) model 
of primary care practice 
support was established 
as a state-wide system 
of care enhancement in 
Massachusetts in 2004 
and has been replicated 
and widely disseminated 
in over 25 other states 
and regions. While 
the use of MCPAP by 
primary care provid-
ers improves access 
to mental health care 
for their patients, the 
program has not been 
evaluated in terms of 
improving mental health 
outcomes compared 
with interventions such 
as screening/referral 
alone. Thus, the overall 
aim of this proposal 
was to evaluate the 
effectiveness of the 
MCPAP model in the 
evaluation and treatment 
of adolescent depres-




and referral support in 
primary care pediatric 
practices. 
The project was 
terminated in its first 
year due to several 
unanticipated obstacles, 
including inability to 
recruit and enroll primary 
care practices in a timely 
fashion and disparate 
medical record systems, 
which made collecting 
comparable data across 
practices challenging 
and demanding on time 
and effort.
Bruce Waslick, MD
1: Johnson KG, Johnson DC, Thomas RJ, Feldmann E, Lindenauer PK, Visintainer P, Kryger MH. Flow 
limitation/obstruction with recovery breath (FLOW) event for improved scoring of mild obstructive sleep 
apnea without electroencephalography. Sleep Med. 2020 Mar;67:249-255.
 2: Johnson KG, Johnson DC, Thomas RJ, Rastegar V, Visintainer P. Cardiovascular and somatic 
comorbidities and sleep measures using three hypopnea criteria in mild obstructive sleep-disordered 
breathing: sex, age, and body mass index differences in a retrospective sleep clinic cohort. J Clin Sleep 
Med. 2020 Oct 15;16(10):1683-1691.
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Closing RPAP statement from 
Paul Visintainer, PhD
A senior military 
commander once rued, 
“No battle plan survives 
contact with the enemy.”  
The same may be said 
of research. Ideas and 
protocols may appear 
elegant and feasible on 
paper, only to fall short 
once they are attempted 
in practice. Consequently, 
the efforts above are not 
without their obstacles. 
For some of the 
studies, the challenges 
proved too substantial 
to overcome, given the 
available time and fund-
ing. Technical barriers at 
the basic science level 
or inability to identify 
and recruit a sufficient 
number eligible patients 
led to early termination of 
studies. It is important to 
recognize, however, that 
this pilot phase is where 
protocols are evaluated 
and refined.  
As William Whewell, a 
historian and philosopher 
noted, “Every failure is a 
step to success”. This is 
the goal of the RPAP – to 
give clinicians who are 
committed to a career in 
research an opportunity 
to present their ideas and 
refined their approaches 
in an effort to develop a 
robust research project. 




The National COVID 
Cohort Collaborative 
(N3C) Data Enclave is 
now open to scientists 
looking for evidence-
based answers to 
COVID-19 research 
questions. This 
centralized and secure 
national data analytics 
platform is for COVID-
19 research, including 
studying potential risk 
factors, protective 
factors and long-term 
health consequences, as 
the pandemic continues 
to evolve. Its data and 







are to support studies 
that impact clinical 
care and research 
methodologies, support 
students/trainees, 
and provide access 
to funds to generate 
pilot and preliminary 
data for external grant 
submissions. For 







funding facilitates the 
development of faculty-
to-faculty networks 
within the University 
system. Visit the 




K-CLUB: Dr. Mihaela 
Stefan has just been 
added as a co-leader. 
Baystate faculty are 




Contact Nate Hafer, 







NEENA QASBA, MD, Access, 
Contraceptive Coverage, 
Expected Supply in our State, 
ACCESS Study Part 3, Baystate 
Health, Inc., RPAP.
CHILD PSYCH
BARRY SARVET, MD, MCPAP 
Medical Director Jul-Dec 2020, 
Beacon Health Options.
EMERGENCY
HOWARD SMITHLINE, MD, 
PReventing Emerging infections 
through Vaccine Effective-
Ness Testing—COVID (Project 
PREVENT), University of CA/LA 
Olive View, CDC.
CRITICAL CARE
JAY STEINGRUB, MD, Surveil-
lance of Respiratory Viruses in 
the Critically Ill: 2020-2021 IVY 
Network Surveillance Study, 
Vanderbilt University Med. Ctr., 
CDC.
JAY STEINGRUB, MD, Phase 
2, Randomized, Double-Blind, 
Placebo-Controlled Study of the 
Effect of Anti-CD14 Treatment 
in Hospitalized Patients with 
COVID-19 (DAIT-COVID-19-003), 
Benaroya Research Inst. (BRI), 
Nat. Inst. Allergy Infec. Disease.
MARK TIDSWELL, MD, A Mul-
ticenter, Adaptive, randomized 
Controlled Platform Trial of Safety 
and Efficacy of Antithrombotic 
Strategies in Hospitalized Adults 
with COVID-19, NYU School of 
Medicine, Nat. Heart Lung Blood 
Inst.
PEDIATRICS
MANDI SUMMERS, FY21 CPS 
Administration, MA Exec. Office 
Public Safety, US Dept. of 
Highway Safety.
Evaluation of AntiGD2-PolyMPC−Dox Prodrugs in a 
Neuroblastoma Tumor Model
Michael Tirabassi, MD, Assistant Professor of Surgery, UMass Medical 
School-Baystate
The use of polymer-
prodrug strategies has 
demonstrated many 
advantages for enhanced 
chemotherapeutic drug 
delivery with improved 
tumor targeting, reduced 
adverse effects, and 
superior efficacy. These 
agents achieve these 
benefits by covalently 
binding the small chemo-
therapeutic molecule to 
a bulky polymer, prevent-
ing the extravasation of 
the drug from systemic 
vascular endothelium 
until it reaches the “leaky” 
tumor bed capillar-
ies. This mechanism 
(known as the enhanced 
permeation and reten-
tion (EPR) effect7-9), 
passively selects for the 
desired site of action and 
promotes drug exposure 
over a longer time-frame, 
resulting in less frequent 
dosing requirements. 
Polymer prodrugs thus 
permit administration of a 
higher maximum tolerated 
dose (MTD), enabling 
delivery of more drug 
to the cancer target 
while reducing off-target 
side-effects. 
The Schneider lab at 
PVLSI has shown that 
polymethacryloyloxy-
ethyl phosphorylcholine 
(polyMPC)  in vivo are 
safe and efficacious in 
toxicity and immunogenic-
ity experiments in mice. 
We proposed to combine 
the benefits of anti-GD2 
immunotherapy with 
the polyMPC prodrug 
platform. Success in this 
project would represent 
a potential breakthrough 
in neuroblastoma by 
decreasing the toxic 
effects, as well as the 
frequency and duration of 
chemotherapy, improving 
their quality of life during 
therapy, in addition to 
their survival. This is a 
cutting-edge approach 
not only for the treatment 
of neuroblastoma, but for 
that of all cancer types. 
While success in this 
project would represent 
a potential breakthrough 
in neuroblastoma 
therapy, the project was 
hampered by techni-
cal hurdle of attaching 
the chemotherapeutic 
molecule to the polymer.  
Consequently, the project 
was halted. As therapeu-
tic polymer formulations 
advance, this project may 
be reconsidered.
Dr. Tirabassi was also 




Laura Sorci, Sr. Clinical 
Research Coordinator, 
was recently appointed 
as a member of the CRA 
Subcommittee of NRG 
Oncology as of January 
2021. Her appointment 
will last for 3 years. She 
is assigned to the Quality 
Control working group 
within the organization. 
This role will be a great 
experience for her and 
Baystate Health as an 
institution.
Her appointment 
reflects her expertise and 
dedication to participating 
in NRG Oncology cancer 
clinical trials.
Congratulations, Laura!
Kudos: Laura Sorci appointed to 
national committe with NRG Oncology
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Remembering Alan Schneyer, PhD, friend and colleague
Alan Schneyer was a 
vital part of the commu-
nity at Baystate Medical 
Center, and therefore, 
his death on November 
18th, 2020 has impacted 
many of us. He was a 
researcher, a teacher, an 
entrepreneur and, most 
valued, he was a friend 
and colleague to many of 
us. Alan was a frequent 
guest for Grand Rounds in 
the Division of Endocrinol-
ogy at Baystate Medical 
Center, invited lecturer 
at UMass Amherst and a 
guest lecturer in courses. 
He was a collaborator in 
science locally as well as 
nationally and internation-
ally. Alan’s obituary can 
be found at bit.ly/3grYZxx. 
His life is a reminder of 
what we have all lost, and 
especially his wife, Elissa 
Brown, and children, Jon 
and Becca.
A Life in Science
After more than 20 
years as a researcher at 
Massachusetts General 
Hospital in Reproduc-
tive Endocrinology, Alan 
was recruited to join 
the Pioneer Valley Life 
Sciences Institute in 2007. 
Alan was a fixture in the 
research community of 
Western Massachusetts 
with faculty appointments 
at both Baystate Medical 
Center and the University 
of Massachusetts-Amherst. 
The move to western Mas-
sachusetts was stimulated 
by his creation of a mouse 
model for polycystic ovar-
ian disease. But his work 
demonstrated unexpected 
effects of follistatin-like 
proteins on the function 
of pancreatic beta cells 
and their role in diabetes. 
This result caused him 
to shift the focus of his 
research to diabetes. He 
could see the potential for 
a completely new strategy 
to manage diabetes. This 
was to devise therapeutics 
to restore the function of 
the pancreatic beta cells 
rather than simply provide 
insulin by daily injections 
to patients. A grand idea, 
but he was unwilling to be 
satisfied with simply an 
idea and he committed 
himself to the task of build-
ing this new therapy.
To support new innova-
tions in diabetes care, 
Alan obtained grants from 
the Juvenile Diabetes 
Research Foundation and 
the National Institutes 
of Health supporting 
his work. But to drive 
this work forward to a 
viable therapeutic would 
require a more focused 
approach. Therefore, in 
2014 he started Fairbanks 
Pharmaceuticals, Inc. The 
company was awarded a 
patent for their therapeutic 
in fall 2020. Fairbanks 
continues with this work 
and will provide a legacy 
that most of us aspire to. 
Some of Alan’s posts can 
be found at the company’s 
website (fairbankspharma.
com/author/aschneyer).
A Friend and Colleague
We remember Alan as 
the indomitable optimist, 
an individual who could 
see opportunities as 
well as the hurdles. He 
provided support for 
those around him. He 
was recognized for his 
patience as a teacher. The 
success of his students 
and staff reflect his ability 
to both communicate 
and stimulate a passion 
for research. For us, Alan 
represented the best of 
science and the effort to 
use science to improve 
the lives of people. 
That included the joy of 
discovery, the challenge 
of wrestling with techni-
cal problems as well as 
developing new therapies 
and the relentless desire 
to never give up on a 
dream. Throughout all 
of this, his compassion 
was ever-present. He 
also brought joy when 
we talked about cycling, 
watching an ultimate 
tournament or discussing 
a weekend with his family. 
Alan was much more than 
a colleague. Though he is 
sorely missed, Alan leaves 
us with many more joys for 
having known and worked 
with him.
Since Dr. Schneyer’s 
death, the work of 
Fairbanks Pharmaceuti-
cals has been continued 
through the leadership of 
his wife, Elissa Schneyer, 
and scientific guidance of 
his collaborator Dr. Melissa 
Brown together with the 
staff at Fairbanks Pharma-
ceuticals. A manuscript 
by the group has been 
accepted for publication 
in Endocrinology and 
will be available online 
shortly. The title is “FSTL3 
Neutralizing Antibodies 
Enhance Glucose-Respon-
sive Insulin Secretion In 
Dysfunctional Male Mouse 
And Human Islets”. This 
work demonstrates the 
efficacy of a new therapy 
for treatment of diabetes 
that serves to preserve the 
function of pancreatic beta 
cells, and thus, delaying 
the need for replacement 
of insulin.
Dr. Alan Schneyer, pictured 
above, passed away on 
November 18, 2020.
Scholarships Available for 
Health Economics & Out-
comes Research (HEOR) 
Certificate Program
Baystate Health 
employees may be 
eligible for a 40% scholar-
ship to the new Cer-
tificate Program in Health 
Economics and Outcomes 
Research (HEOR)!
The HEOR Program 
is offered by the Tufts 
University Graduate 
School of Biomedical 
Sciences (GSBS) Clinical 
and Translational Science 
(CTS) Graduate Program, 
and is co-directed by 
David Kent, MD, CM, MSc, 
Director of the CTS Gradu-
ate Program, and Peter 
Neumann, ScD, Director of 
the Center for Evaluation 
of Value and Risk (CEVR).
Individuals seeking an 
introduction to HEOR, 
including clinicians and 
other health care profes-
sionals, professionals in 
the pharmaceutical and 
biotechnology industry, 
graduate degree holders, 
and graduate degree 
students, are encouraged 
to apply.
The Program is 
designed to accommodate 
the schedules of learners 
who are already immersed 
in professional careers or 
other training programs. 
To apply for a scholarship, 
please email Elizabeth 
Leary, PhD, Graduate 
Program Manager, at 
ewiltrout@tuftsmedical-
center.org. 
Introducing Tufts CTSI I 
LEARN!
Tufts Clinical and Trans-
lational Science Institute 
(CTSI) recently launched 
Tufts CTSI I LEARN (ilearn.
tuftsctsi.org), a modern, 
interactive online learning 
portal offering non-degree 
professional education 
and training opportunities 
in clinical and translational 
research. 
Tufts CTSI I LEARN 
includes live-streamed, 
blended synchronous and 
asynchronous courses, 
self-paced courses, 
and recorded seminars, 
workshops, and trainings 
to support the professional 
development of research 
stakeholders including 
investigators, coordinators, 
community members, and 
research participants. The 
user-friendly platform was 




in exploring Tufts CTSI 
I LEARN should create 
a free user account to 
access more than 100 
learning opportunities. 
Users of the original 
I LEARN platform will 
need to register for new 
accounts. With a Tufts 
CTSI I LEARN account, 
users can keep track of 
their courses and earn 




News from Tufts CTSI
We are interested in ensuring that Baystate employees and patients (and their families) are aware of the important 
research that goes on at Baystate and how it contributes to better patient care. The Innovator welcomes feedback 
and story ideas. Contact Allison Billeter at allison.billeter@baystatehealth.org to submit yours.
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